Weight-loss drugs could prevent fatal complications from heart attacks, UK study finds
The study, conducted in the UK, suggests that weight-loss drugs like Ozempic and Wegovy may help prevent fatal complications in people who have had a heart attack. The research, based on animal model trials, found that these GLP-1 drugs can reduce the risk of 'no-reflow', a problem that affects up to half of the 100,000 people in the UK who suffer a heart attack each year. The 'no-reflow' phenomenon is a condition where the blood flow to the heart is not restored properly after a heart attack, leading to further tissue damage. The study indicates that the use of these weight-loss drugs could potentially help prevent this life-threatening complication, which often occurs during the recovery process following a heart attack. The findings of this study offer hope for a new approach to improving outcomes for heart attack patients and reducing the risk of fatal complications.
Source: For the complete article, please visit the original source link below.
